Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report.
The Health Resources and Services Administration, an HHS agency, reported that 340B covered entities purchased $81.4 billion in outpatient drugs through the 340B program in 2024. Disproportionate share hospitals spent about $64.13 billion, children’s hospitals $2.37 billion, critical access hospitals $1.19 billion, sole community hospitals $549 million, and freestanding cancer centers $602 million.
About 31% of the $81.4 billion was spent on 10 medications, according to the report.
The brand names of the 10 drugs with the highest expenditures in the 340B program last year were:
1. Keytruda (oncology) — $8.16 billion
2. Biktarvy (HIV) — $4.2 billion
3. Darzalex Faspro (oncology) — $2.46 billion
4. Opdivo (oncology) — $2.15 billion
5. Trikafta (cystic fibrosis) — $2.07 billion
6. Ocrevus (multiple sclerosis) — $1.97 billion
7. Descovy (HIV) — $1.18 billion
8. Stelara (immunology) — $1.11 billion
9. Imfinzi (oncology) — $1.09 billion
10. Entyvio (immunology) — $968 million
